Agno Pharma, a CDMO specializing in small-molecule active pharmaceutical ingredients (APIs) and critical GMP intermediates announced the acquisition of Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon.
With over 20 years history, the Eugene site brings a strong legacy in small-molecule API development and manufacturing, anchored by a 16,000 square-foot R&D lab facility as well as a newly constructed 30,000 square-foot manufacturing facility, equipped with state-of-the-art GMP infrastructure supporting early-phase to late-phase clinical API production. Under Actylis, the Eugene site received significant investment to expand and upgrade its GMP manufacturing operations, and represents a robust platform well positioned for future growth.
“We would like to thank Actylis for its investments and stewardship of the Eugene site, and we are extremely excited to welcome the Eugene team into the Agno Pharma platform,” said James Chen, PhD, Chief Executive Officer of Agno Pharma. “This acquisition is a transformative step forward in building a differentiated development and manufacturing hub. The Eugene site brings technical depth in early-phase API development and its high-quality GMP infrastructure will be a powerful driver of new business as we support innovative biotech and pharmaceutical partners developing novel chemical entities.”